President Donald Trump said Thursday his administration has reached an agreement with drugmakers Novo Nordisk and Eli Lilly to lower the cost of their blockbuster GLP-1 weight loss drugs, Wegovy and Zepbound, respectively.

Under the deal, the monthly out-of-pocket cost of the drugs could range from $50 to $350, depending on the dosage and insurance coverage, a senior administration official said.

Currently, Zepbound and Wegovy carry list prices above $1,000 a month, although both companies have introduced lower cost options for patients paying in cash and purchasing the drugs directly through their websites. To further expand access, Costco recently announced it would sell Wegovy and Ozempic for $499 for people who paid cash, while Walmart launched a similar arrangement with Lilly’s

See Full Page